Question

consider this claim: prescription drugs should not be advertised directly to consumers because of the potential risk of misinforming the public. which is the strongest evidence to support the claim? researchers at dartmouth college analyzed pharmaceutical spending trends over a twenty - year span and found that spending on consumer direct - to - consumer advertisements increased from $2.1 billion in 1997 to $9.6 billion in 2016. according to a study published in a medical journal, fifty - five percent of the claims made in drug ads to consumers were considered “potentially misleading” and two percent were “false.” a survey investigating the consumer impact of advertisements for prescription drugs found that one - third of respondents have asked their doctors for more information about a drug they learned about from an ad.

Explanation:

The claim is about the risk of misinforming the public through direct - to - consumer prescription drug advertising. The second option directly addresses the content of drug ads, stating that a significant portion (55%) of claims were "potentially misleading" and 2% were "false". This directly relates to the misinformation risk mentioned in the claim. The first option only talks about spending on ads, which is not directly related to misinformation. The third option is about consumers asking for more info, not about the ads being misinformative.

Answer:

According to a study published in a medical journal, fifty - five percent of the claims made in drug ads to consumers were considered "potentially misleading" and two percent were "false."